Abstract:

[Abstract]   Objective   To evaluate the changes of platelet activity before and after anti-platelet treatment in pa?
tients with coronary heart disease, and their responsiveness to clopidogrel through detecting the phosphorylation levels of vasodilator stimulated phosphoprotein (VASP).   Methods   Twenty-eight cases of healthy people were selected as control group . Patients with chronic stable angina pectoris (CSA, n=95) were randomly divided into A (48 cases) group and B (47 cases) group,and were given clopidogrel 75 mg/d or 150 mg/d respectively; Patients with non ST segment elevation acute coronary syndrome (NST-ACS, n=67) were all given 300 mg loading dose of clopidogrel at the first time, then randomly divided into C (33 cases) group and D (34 cases) group, and given clopidogrel 75 mg/d and 150 mg/d respectively. Blood were taken to examine the phosphorylation levels of serum VASP by ELISA before taking clopidogrel, at time point of loading dose and the fifth day of clopidogrel administration .   Results   Before treatment, phosphorylation levels of serum VASP were lower in A, B, C, D groups than those in the normal control group(P＜ 0.05). After treatment of clopidogrel for 5 days: ① In group A and group B ,phosphorylation levels of serum VASP did not change compared to that before treatment (P＞ 0.05). ② In group C and group D, phosphorylation levels of serum VASP were significantly increased at loading dose and the fifth day of clopidogrel administration than those before treatment (P < 0.05), but there were no significant differences in phosphorylation level of VASP was lower group between group C and group D after serum treatment (P > 0.05).   Conclusion     The
phosphorylation level of serum VASP was lower in patients with coronary heart disease than that in normal control group. Clopidogrel can improve the phosphorylation level of serum VASP in NST-ACS patients .

Key words: Coronary artery Disease, Clopidogrel, Vasodilator-stimulated phosphoprotein, Platelet activation